EUA is precisely for that: Quote: - The FDA ac
Post# of 148151
Quote:
- The FDA acknowledged that normal P-Factor is not the bar they want to set to evaluate Treatments for S/C during a pandemic.
- If any Treatment shows good improvement over SOC for S/C patients, the FDA will be inclined to offer an EUA and continue evaluating said Treatment for either full approval or discontinuance of the EUA.
- S/C patients have no choice. Any Treatment that is SAFE and gives them a better chance of survival WILL receive an EUA as the alternative is death.
- The FDA will be looking to pair up viable drugs to improve that chance of survival through partnerships.
Read More: https://investorshangout.com/post/view?id=607...z6oLwoOaEt
_________________________
Unfortunately, this "quote" has never been, to the best of my knowledge, proven to be a quote from an FDA document.
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.